Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight ...

Annual Congress, CureGene Pharmaceuticals ("CureGene") announced late-breaking preclinical results for its investigational liver-targeted thyroid hormone receptor beta (THR-β) prodrug, CG-0416.

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

GEMMA Collins revealed she is slimming down faster than ever as she updated fans on her health journey. The TOWIE star, 44, has gone from a size 26 to a size 20 in just three-months since starting ...

Trials have confirmed the efficacy of GLP-1 RAs in achieving clinically sustained weight loss in people with obesity without diabetes.

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...